Okada, Yusuke

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy Division of Drug Development and Regulatory Science (Shiba-Kyoritsu)

Position

Research Associate/Assistant Professor/Instructor
Page Top ▲

Academic Background 【 Display / hide 】

  • 2008.04
    -
    2014.03

    Nagoya City University, Faculty of Pharmaceutical Sciences

    University, Graduated

  • 2019.04
    -
    2023.03

    Meiji Pharmaceutical University

    Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • Ph.D., Meiji Pharmaceutical University, Coursework, 2023.03

Page Top ▲
 

Papers 【 Display / hide 】

  • Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET(®) in Japan.

    Okada Y, Kajiyama K, Ishiguro C, Nonaka T, Komaki T, Kuga W, Komiyama N, Iguchi T, Horiuchi N, Uyama Y

    The Journal of dermatological treatment 35 ( 1 ) 2373826 2024.12

    Research paper (scientific journal), Lead author, Accepted,  ISSN  0954-6634

  • Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses

    Y Okada, K Inada, M Akazawa

    Journal of Clinical Psychopharmacology 44 (3), 263-271 44 ( 3 ) 263 - 271 2024.05

    Research paper (scientific journal), Lead author, Accepted,  ISSN  0271-0749

  • Prescription trend and lactic acidosis in patients prescribed metformin before and after the revision of package insert for allowing metformin administration to patients with …

    T Waki, Y Okada, Y Kinoshita, K Kajiyama, C Ishiguro, Y Nakazato, ...

    Frontiers in Medicine 10, 1294696  2024

    Research paper (scientific journal), Accepted

  • Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan

    Y Okada, K Inada, M Akazawa

    Schizophrenia Research 252, 300-308 (Elsevier {BV})  252   300 - 308 2023.02

    Research paper (scientific journal), Lead author, Accepted,  ISSN  0920-9964

  • Effects of medical service fee revision on reducing irrational psychotropic polypharmacy in Japan: an interrupted time-series analysis

    Y Okada, M Akazawa

    Social Psychiatry and Psychiatric Epidemiology, 1-12 (Springer Science and Business Media {LLC})  57 ( 2 ) 411 - 422 2022.02

    Research paper (scientific journal), Lead author, Accepted,  ISSN  0933-7954

    　View Summary

    <jats:title>Abstract</jats:title><jats:sec>
    <jats:title>Purpose</jats:title>
    <jats:p>According to the revised Japanese medical service fees aimed at reducing irrational psychotropic polypharmacy, medical service fees are reduced if the number of simultaneously prescribed psychotropic drugs exceeds the standard. This study primarily aims to examine the effect of the 2018 revision.</jats:p>
    </jats:sec><jats:sec>
    <jats:title>Methods</jats:title>
    <jats:p>Using a large Japanese administrative claims database, we retrospectively identified five groups (April 2013–September 2018) prescribed at least one drug from the following drug groups: anxiolytics, hypnotics, sum of anxiolytics and hypnotics, antipsychotics, and antidepressants (study population in each group: 547,511, 406,524, 759,137, 112,929, and 201,046, respectively). We used an interrupted time-series design to evaluate changes in the proportion of patients prescribed more than the standard number of drugs.</jats:p>
    </jats:sec><jats:sec>
    <jats:title>Results</jats:title>
    <jats:p>After the 2018 revision, the proportion of patients prescribed more than the standard number of drugs significantly decreased only for the sum of anxiolytics and hypnotics; estimated changes in level and trend were − 0.60% [− 0.69%, − 0.52%] and − 0.04% [− 0.06%, − 0.02%] per month, respectively. The proportion of patients exhibiting a decrease in the number of prescribed drugs from more than the standard to within the standard increased when the revision was enforced (April 2018); this proportion in April 2018 was 36.3%, while all other proportions were in the range of 12.1–22.3%.</jats:p>
    </jats:sec><jats:sec>
    <jats:title>Conclusion</jats:title>
    <jats:p>The 2018 revision promoted a reduction in the number of prescribed drugs, which served as an important factor in the decrease in the proportion of patients prescribed more than the standard number of drugs for the sum of anxiolytics and hypnotics.</jats:p>
    </jats:sec>

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • 【MID-NET運用開始5周年を迎えて】MID-NETのこれまでと今後　大切にしてきたこと

    關野 一石, 中野 千佳子, 村山 一茂, 高橋 史峰, 飛知和 康史, 原田 紗世子, 大田 有佳里, 岸塲 真理, 堀木 稚子, 梶山 和浩, 岡田 佑輔, 山口 光峰, 宇山 佳明

    レギュラトリーサイエンス学会誌 ((一社)レギュラトリーサイエンス学会)  14 ( 1 ) 107 - 122 2024.01

    ISSN  2185-7113

    　View Summary

    MID-NETは,2018年4月1日から本格運用を開始し,2023年4月をもち運用開始5周年を迎えた.MID-NETの概要とこれまでの取り組みについて述べるともに,MID-NET運営を行う上で大切にしてきたこと,アウトカムバリデーションの取り組み,独立行政法人医薬品医療機器総合機構(PMDA)がMID-NETを活用した事例について紹介したい.(著者抄録)

  • 今月のTopic　市販後安全対策　MID-NETを活用した早期安全性シグナルモニタリングについて

    岡田 佑輔, 野中 孝浩, 宇山 佳明

    医薬品医療機器レギュラトリーサイエンス ((一財)医薬品医療機器レギュラトリーサイエンス財団)  52 ( 8 ) 646 - 648 2021.12

    ISSN  1884-6076

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • STUDY OF MAJOR FIELD: (DRUG DEVELOPMENT AND REGULATORY SCIENCE)

    2024

  • SEMINAR: (DRUG DEVELOPMENT AND REGULATORY SCIENCE)

    2024

  • RESEARCH FOR BACHELOR'S THESIS 1

    2024

  • REGULATORY SCIENCE ADVANCED COURSE

    2024

  • PHARMACEUTICAL-ENGLISH SEMINAR

    2024

display all >>

Page Top ▲